Association of Gene Mutations with Response to Arsenic-Containing Compound Qinghuang Powder () in Patients with Myelodysplastic Syndromes.
10.1007/s11655-018-2977-3
- Author:
Pan ZHAO
1
;
Jun-Bin LIANG
2
;
Zhong-Yang DENG
1
;
Ming-Jing WANG
1
;
Jia-Yue QIN
2
;
Chong-Jian CHEN
3
;
Xiao-Mei HU
4
Author Information
1. Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
2. Annoroad Gene Technology Co. Ltd., Beijing, 100176, China.
3. Annoroad Gene Technology Co. Ltd., Beijing, 100176, China. cchen@annoroad.com.
4. Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. huxiaomei_2@163.com.
- Publication Type:Journal Article
- Keywords:
arsenic;
myelodysplastic syndromes;
next-generation sequencing;
realgar
- From:
Chinese journal of integrative medicine
2019;25(6):409-415
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:To investigate the relationship between gene mutations and response to Compound Qinghuang Powder (, CQHP) in patients with myelodysplastic syndrome (MDS).
METHODS:Forty-three MDS patients were genotyped by ultra-deep targeted sequencing and the clinical data of patients were collected and the relationship between them was analyzed.
RESULTS:Up to 41.86% of patients harbored genet mutations, in most cases with more than one mutation. The most common mutations were in SF3B1, U2AF1, ASXL1, and DNMT3A. After treatment with CQHP, about 88.00% of patients no longer required blood transfusion, or needed half of prior transfusions.
CONCLUSIONS:CQHP is an effective treatment for patients with MDS, especially those with gene mutations in SF3B1, DNMT3A, U2AF1, and/or ASXL1.
